Medindia

X

Bayer's Prostate Cancer Drug- Alpharadin Successful in Phase III Trials

by Dr. Trupti Shirole on  June 6, 2011 at 10:00 PM Cancer News   - G J E 4
German pharmaceutical company Bayer AG has been asked to stop the phase III trials of the drug Alpharadin. Patients who were receiving placebo will be offered the new medicine. The safety and tolerability of Alpharadin were consistent during Phase I and Phase II trial outcomes.
 Bayer's Prostate Cancer Drug- Alpharadin Successful in Phase III Trials
Bayer's Prostate Cancer Drug- Alpharadin Successful in Phase III Trials
Advertisement

Alpharadin, or radium-223 chloride is exclusively licensed from Norwegian partner Algeta ASA. The drug met its primary endpoint by improving overall survival significantly in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases.

Advertisement
The median overall survival rate was 14 months for patients treated with Alpharadin, compared with 11.2 months.


Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All